BR112015013557B1 - Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante - Google Patents
Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante Download PDFInfo
- Publication number
- BR112015013557B1 BR112015013557B1 BR112015013557-9A BR112015013557A BR112015013557B1 BR 112015013557 B1 BR112015013557 B1 BR 112015013557B1 BR 112015013557 A BR112015013557 A BR 112015013557A BR 112015013557 B1 BR112015013557 B1 BR 112015013557B1
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- cells
- cell
- heterologous
- peptide
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 454
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 446
- 230000027455 binding Effects 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims abstract description 65
- 230000000694 effects Effects 0.000 title claims abstract description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 title claims description 52
- 150000001413 amino acids Chemical group 0.000 title claims description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 title description 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 181
- 239000003446 ligand Substances 0.000 claims abstract description 83
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 16
- 229920001184 polypeptide Polymers 0.000 claims abstract description 13
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 456
- 102000034287 fluorescent proteins Human genes 0.000 claims description 125
- 108091006047 fluorescent proteins Proteins 0.000 claims description 125
- 230000014509 gene expression Effects 0.000 claims description 88
- 102000014914 Carrier Proteins Human genes 0.000 claims description 61
- 108091008324 binding proteins Proteins 0.000 claims description 59
- 239000002773 nucleotide Substances 0.000 claims description 41
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 239000013598 vector Substances 0.000 claims description 33
- 230000001086 cytosolic effect Effects 0.000 claims description 30
- 239000000725 suspension Substances 0.000 claims description 18
- 230000008045 co-localization Effects 0.000 claims description 17
- 238000005406 washing Methods 0.000 claims description 17
- 210000004962 mammalian cell Anatomy 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 12
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 11
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 11
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 11
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 11
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 10
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 10
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 10
- 238000012163 sequencing technique Methods 0.000 claims description 9
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims description 8
- 102000027257 transmembrane receptors Human genes 0.000 claims description 8
- 108091008578 transmembrane receptors Proteins 0.000 claims description 8
- 102000002356 Nectin Human genes 0.000 claims description 7
- 108060005251 Nectin Proteins 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 5
- 108010012236 Chemokines Proteins 0.000 claims description 5
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 5
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 5
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 5
- 102100034980 ICOS ligand Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108090000862 Ion Channels Proteins 0.000 claims description 5
- 102000004310 Ion Channels Human genes 0.000 claims description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 5
- 108020000411 Toll-like receptor Proteins 0.000 claims description 5
- 102000002689 Toll-like receptor Human genes 0.000 claims description 5
- 102000002467 interleukin receptors Human genes 0.000 claims description 5
- 108010093036 interleukin receptors Proteins 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 108090000301 Membrane transport proteins Proteins 0.000 claims description 2
- 102000003939 Membrane transport proteins Human genes 0.000 claims description 2
- 230000003993 interaction Effects 0.000 abstract description 68
- 235000018102 proteins Nutrition 0.000 description 359
- 238000002493 microarray Methods 0.000 description 83
- 239000004005 microsphere Substances 0.000 description 75
- 102000005962 receptors Human genes 0.000 description 67
- 108020003175 receptors Proteins 0.000 description 67
- 239000005090 green fluorescent protein Substances 0.000 description 66
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 59
- 230000001413 cellular effect Effects 0.000 description 26
- 238000013459 approach Methods 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 21
- 230000004927 fusion Effects 0.000 description 20
- 108010052285 Membrane Proteins Proteins 0.000 description 18
- 102000018697 Membrane Proteins Human genes 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 239000011324 bead Substances 0.000 description 11
- 238000012350 deep sequencing Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000007885 magnetic separation Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000004850 protein–protein interaction Effects 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000008611 intercellular interaction Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000012775 microarray technology Methods 0.000 description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 210000000428 immunological synapse Anatomy 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960005347 belatacept Drugs 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 108091008034 costimulatory receptors Proteins 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 102000027596 immune receptors Human genes 0.000 description 2
- 108091008915 immune receptors Proteins 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229940035567 orencia Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 108010084420 scavidin Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000000529 Costimulatory and Inhibitory T-Cell Receptors Human genes 0.000 description 1
- 108010041504 Costimulatory and Inhibitory T-Cell Receptors Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000027583 GPCRs class C Human genes 0.000 description 1
- 108091008882 GPCRs class C Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- -1 ICOS Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010023439 Kidney transplant rejection Diseases 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 206010025671 Malignant melanoma stage IV Diseases 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 101710159648 Uncharacterized protein Proteins 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000013090 high-throughput technology Methods 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000009428 plumbing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261735791P | 2012-12-11 | 2012-12-11 | |
| US61/735,791 | 2012-12-11 | ||
| US201361833588P | 2013-06-11 | 2013-06-11 | |
| US61/833,588 | 2013-06-11 | ||
| PCT/US2013/073275 WO2014093118A1 (en) | 2012-12-11 | 2013-12-05 | Methods for high throughput receptor:ligand identification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015013557A2 BR112015013557A2 (pt) | 2020-01-14 |
| BR112015013557B1 true BR112015013557B1 (pt) | 2021-12-14 |
Family
ID=50934838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015013557-9A BR112015013557B1 (pt) | 2012-12-11 | 2013-12-05 | Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10048271B2 (https=) |
| EP (2) | EP2931949B1 (https=) |
| JP (2) | JP2016500255A (https=) |
| KR (1) | KR102208505B1 (https=) |
| CN (2) | CN109324190A (https=) |
| AU (2) | AU2013359907B2 (https=) |
| BR (1) | BR112015013557B1 (https=) |
| CA (1) | CA2894511C (https=) |
| IL (2) | IL239096B (https=) |
| SG (2) | SG10201808463RA (https=) |
| WO (1) | WO2014093118A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2894511C (en) | 2012-12-11 | 2021-12-07 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for high throughput receptor:ligand identification |
| CA2954360C (en) | 2014-07-07 | 2022-11-22 | Johan ELF | Phenotypic characterization and in situ genotyping of a library of genetically different cells |
| WO2017201210A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN109689096A (zh) * | 2016-05-18 | 2019-04-26 | 阿尔伯特爱因斯坦医学院公司 | 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法 |
| JP7019171B2 (ja) * | 2016-11-24 | 2022-02-15 | 国立研究開発法人物質・材料研究機構 | 細胞表面に存在する分子の結合による細胞間相互作用を計測する方法 |
| WO2018111941A1 (en) * | 2016-12-12 | 2018-06-21 | 13.8, Inc. | Compositions of high affinity reagents and methods of use thereof |
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| JP2020534352A (ja) | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| WO2021219807A1 (en) * | 2020-04-30 | 2021-11-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Pd-l1 variants with improved affinity towards pd-1 |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| US5869270A (en) | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| US6211342B1 (en) | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| US20050003431A1 (en) | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| US7098306B2 (en) | 1997-02-13 | 2006-08-29 | The Regents Of The University Of California | Method and compositions for treating hepatocellular cancer |
| JP3816959B2 (ja) | 1997-02-13 | 2006-08-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 肝細胞癌の予防および処置 |
| US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| US20030007978A1 (en) | 1997-09-16 | 2003-01-09 | Burrows Gregory G. | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| US6696304B1 (en) | 1999-02-24 | 2004-02-24 | Luminex Corporation | Particulate solid phase immobilized protein quantitation |
| US7446189B1 (en) | 1999-04-30 | 2008-11-04 | Institut De Recherches Cliniques De Montreal | Nucleic acids encoding mutant human CD80 and compositions comprising the same |
| US20020006664A1 (en) | 1999-09-17 | 2002-01-17 | Sabatini David M. | Arrayed transfection method and uses related thereto |
| EP1287363A2 (en) | 2000-05-25 | 2003-03-05 | Sunol Molecular Corporation | Modulation of t-cell receptor interactions |
| US20020122820A1 (en) | 2001-01-16 | 2002-09-05 | Hildebrand William H. | Soluble MHC artificial antigen presenting cells |
| US6800748B2 (en) * | 2001-01-25 | 2004-10-05 | Large Scale Biology Corporation | Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector |
| DK2336167T3 (da) | 2001-03-14 | 2019-09-02 | Dako Denmark As | MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi |
| WO2002093129A2 (en) * | 2001-05-15 | 2002-11-21 | University Of Medicine & Dentistry Of New Jersey | Methods for analyzing interactions between proteins in live and intact cells |
| KR20040032105A (ko) | 2001-06-04 | 2004-04-14 | 엠엘 래보러토리즈 피엘씨 | 재조합 단백질의 조성물 및 재조합 단백질의 고수준대규모 생산방법 |
| US20030017134A1 (en) | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| AU2002368044A1 (en) | 2001-06-22 | 2004-04-19 | Maxygen, Inc. | Co-stimulatory molecules |
| AU2002322211A1 (en) | 2001-07-12 | 2003-01-29 | Canvac | Methods and compisitions for activation human t cells in vitro |
| WO2003040307A2 (en) | 2001-07-27 | 2003-05-15 | Human Genome Sciences, Inc. | Heteromultimeric tnf ligand family members |
| DK1454138T3 (da) | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
| EP1599502A1 (en) | 2003-02-27 | 2005-11-30 | TheraVision GmbH | A molecule which binds cd80 and cd86 |
| AU2003901876A0 (en) | 2003-04-17 | 2003-05-08 | The Macfarlane Burnet Institute For Medical Research And Public Health | Viral vector |
| US20050042641A1 (en) | 2003-05-27 | 2005-02-24 | Cold Spring Harbor Laboratory | In vivo high throughput selection of RNAi probes |
| US7470513B2 (en) | 2003-11-10 | 2008-12-30 | Academia Sinica | Risk assessment for adverse drug reactions |
| US20060234205A1 (en) | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| AU2005247950B2 (en) | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| EP1945662A2 (en) * | 2005-11-10 | 2008-07-23 | Receptor Biologix, Inc. | Methods for production of receptor and ligand isoforms |
| US8518697B2 (en) | 2006-04-04 | 2013-08-27 | Washington University | Single chain trimers and uses therefor |
| KR101442209B1 (ko) | 2006-05-19 | 2014-11-18 | 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. | 융합 단백질, 이의 용도 및 이의 제조방법 |
| EP1889851A1 (en) | 2006-08-18 | 2008-02-20 | Charite Universitätsmedizin-Berlin | PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies |
| US8992937B2 (en) | 2006-08-28 | 2015-03-31 | Washington University | Disulfide trap MHC class I molecules and uses therefor |
| EP2341142B8 (en) | 2006-12-28 | 2015-01-14 | International Institute of Cancer Immunology, Inc. | HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising same |
| CN103736086A (zh) | 2007-02-15 | 2014-04-23 | 曼康公司 | 用于增强t细胞应答的方法 |
| WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| US9394571B2 (en) | 2007-04-27 | 2016-07-19 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US8926961B2 (en) | 2007-10-03 | 2015-01-06 | Board Of Trustees Of The University Of Arkansas | HPV E6 protein T cell epitopes and uses thereof |
| CN101418309B (zh) | 2007-10-23 | 2011-05-04 | 中国农业科学院上海兽医研究所 | 柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用 |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| EP2184070A1 (en) | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G proteins and pharmaceutical uses thereof |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| EP2445935B1 (en) | 2009-06-25 | 2015-07-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof |
| WO2011066342A2 (en) * | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2504364T3 (pl) * | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US8507222B2 (en) * | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| WO2012127464A2 (en) | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| CN103649125A (zh) | 2011-06-22 | 2014-03-19 | 霍夫曼-拉罗奇有限公司 | 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞 |
| CN103796681B (zh) | 2011-06-30 | 2018-07-20 | 建新公司 | T细胞活化的抑制剂 |
| WO2013030620A2 (de) | 2011-08-30 | 2013-03-07 | Jacobs University Bremen Ggmbh | Gen codiert für ein mhc-klasse-i-molekül, plasmid, expressionssystem protein, multimer, reagenz und kit zum analysieren einer t-zellen-frequenz |
| US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| KR101764096B1 (ko) * | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| AU2013207669C1 (en) | 2012-01-13 | 2018-05-31 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| WO2013116656A1 (en) | 2012-02-03 | 2013-08-08 | Emory University | Immunostimulatory compositions, particles, and uses related thereto |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| RU2015125639A (ru) | 2012-11-30 | 2017-01-10 | Роше Гликарт Аг | Удаление раковых клеток с помощью циркулирующих вирус-специфических цитотоксических т-клеток с использованием направленных против раковых клеток многофункциональных белков, содержащих молекулу гкгс класса i |
| CA2894511C (en) | 2012-12-11 | 2021-12-07 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for high throughput receptor:ligand identification |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| SG11201507883SA (en) | 2013-03-29 | 2015-10-29 | Sumitomo Dainippon Pharma Co Ltd | Wt1-antigen peptide conjugate vaccine |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| SG11201605632SA (en) | 2014-01-21 | 2016-08-30 | Einstein Coll Med | Cellular platform for rapid and comprehensive t-cell immunomonitoring |
| US20160152725A1 (en) | 2014-02-25 | 2016-06-02 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide |
| JP6005305B2 (ja) | 2014-02-26 | 2016-10-12 | テラ株式会社 | Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤 |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| WO2015195531A2 (en) | 2014-06-18 | 2015-12-23 | Albert Einstein College Of Medicine, Inc. | Syntac polypeptides and uses thereof |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| PT3172227T (pt) | 2014-07-21 | 2019-12-06 | Delinia Inc | Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis |
| CA2957717C (en) | 2014-08-12 | 2021-10-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein |
| JP2017525370A (ja) | 2014-08-21 | 2017-09-07 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法 |
| DK3186283T3 (da) | 2014-08-29 | 2020-03-02 | Hoffmann La Roche | Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1 |
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| CA2993429A1 (en) | 2015-07-31 | 2017-02-09 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
| CN106565836B (zh) | 2015-10-10 | 2020-08-18 | 中国科学院广州生物医药与健康研究院 | 高亲和力的可溶性pdl-1分子 |
| WO2017151818A2 (en) | 2016-03-02 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CA3014466A1 (en) | 2016-03-03 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| JP7422480B2 (ja) | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| CN109689096A (zh) | 2016-05-18 | 2019-04-26 | 阿尔伯特爱因斯坦医学院公司 | 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法 |
| WO2019051126A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF |
-
2013
- 2013-12-05 CA CA2894511A patent/CA2894511C/en active Active
- 2013-12-05 WO PCT/US2013/073275 patent/WO2014093118A1/en not_active Ceased
- 2013-12-05 JP JP2015545835A patent/JP2016500255A/ja not_active Ceased
- 2013-12-05 BR BR112015013557-9A patent/BR112015013557B1/pt not_active IP Right Cessation
- 2013-12-05 AU AU2013359907A patent/AU2013359907B2/en not_active Ceased
- 2013-12-05 EP EP13862361.6A patent/EP2931949B1/en active Active
- 2013-12-05 CN CN201811139644.3A patent/CN109324190A/zh active Pending
- 2013-12-05 CN CN201380071758.8A patent/CN105121715B/zh not_active Expired - Fee Related
- 2013-12-05 US US14/649,176 patent/US10048271B2/en active Active
- 2013-12-05 SG SG10201808463RA patent/SG10201808463RA/en unknown
- 2013-12-05 KR KR1020157017981A patent/KR102208505B1/ko not_active Expired - Fee Related
- 2013-12-05 EP EP19197120.9A patent/EP3640375A3/en not_active Withdrawn
- 2013-12-05 SG SG11201504558TA patent/SG11201504558TA/en unknown
-
2015
- 2015-05-31 IL IL239096A patent/IL239096B/en active IP Right Grant
-
2018
- 2018-03-14 AU AU2018201812A patent/AU2018201812B2/en not_active Ceased
- 2018-07-25 US US16/044,608 patent/US11226339B2/en active Active
- 2018-11-05 IL IL262785A patent/IL262785B/en active IP Right Grant
-
2019
- 2019-11-05 JP JP2019200491A patent/JP7128792B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160011204A1 (en) | 2016-01-14 |
| CN105121715A (zh) | 2015-12-02 |
| IL239096A0 (en) | 2015-07-30 |
| EP3640375A2 (en) | 2020-04-22 |
| AU2013359907A1 (en) | 2015-06-18 |
| CA2894511A1 (en) | 2014-06-19 |
| SG11201504558TA (en) | 2015-07-30 |
| US11226339B2 (en) | 2022-01-18 |
| US20200011875A1 (en) | 2020-01-09 |
| SG10201808463RA (en) | 2018-11-29 |
| IL262785B (en) | 2020-04-30 |
| EP3640375A3 (en) | 2020-07-29 |
| IL239096B (en) | 2019-03-31 |
| KR20150094674A (ko) | 2015-08-19 |
| JP2016500255A (ja) | 2016-01-12 |
| JP7128792B2 (ja) | 2022-08-31 |
| AU2013359907B2 (en) | 2018-01-18 |
| BR112015013557A2 (pt) | 2020-01-14 |
| CN105121715B (zh) | 2018-10-26 |
| KR102208505B1 (ko) | 2021-01-27 |
| HK1218144A1 (zh) | 2017-02-03 |
| CA2894511C (en) | 2021-12-07 |
| WO2014093118A1 (en) | 2014-06-19 |
| EP2931949B1 (en) | 2019-09-18 |
| US10048271B2 (en) | 2018-08-14 |
| AU2018201812A1 (en) | 2018-04-05 |
| AU2018201812B2 (en) | 2020-09-10 |
| EP2931949A4 (en) | 2016-07-27 |
| IL262785A (en) | 2018-12-31 |
| JP2020043860A (ja) | 2020-03-26 |
| CN109324190A (zh) | 2019-02-12 |
| EP2931949A1 (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11226339B2 (en) | Methods for high throughput receptor:ligand identification | |
| US12460199B2 (en) | Modular polypeptide libraries and methods of making and using same | |
| US9732392B2 (en) | Modular sensor architecture for cell based biosensors | |
| Garrett-Thomson et al. | Mechanistic dissection of the PD-L1: B7-1 co-inhibitory immune complex | |
| Zhai et al. | In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1 | |
| US20220348657A1 (en) | Bioassay for t-cell co-stimulatory proteins containing fc domains | |
| KR102728630B1 (ko) | 게놈-규모 t 세포 활성 어레이 및 그의 사용 방법 | |
| Ludwig et al. | High‐throughput single‐cell sequencing of paired TCRα and TCRβ genes for the direct expression‐cloning and functional analysis of murine T‐cell receptors | |
| Chen et al. | Cell surface protein–protein interaction profiling for biological network analysis and novel target discovery | |
| HK1218144B (zh) | 高通量受体:配体鉴定方法 | |
| Linhares et al. | Transcriptional reprogramming via signaling domains of CD2, CD28, and 4-1BB | |
| HK40069214B (en) | Modular polypeptide libraries and methods of making and using same | |
| HK40104037A (en) | Modular polypeptide libraries and methods of making and using same | |
| HK1256838B (en) | Modular polypeptide libraries and methods of making and using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: COM AFFILIATION, INC. (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE (US) |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2804 DE 01-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |